Letter · 2022
Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials
The Lancet Oncology, 23(11), e480 · Published 31 October 2022 · DOI 10.1016/s1470-2045(22)00628-3
In brief
“Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials” is a 2022 letter by Frédéric Fiteni, published in The Lancet Oncology. OpenAlex counts 0 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 0
- References
- 3
- Authors
- 1
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Fiteni, F. (2022). Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials. The Lancet Oncology, 23(11), e480. https://doi.org/10.1016/s1470-2045(22)00628-3
MLA 9
Fiteni, Frédéric. “Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials.” The Lancet Oncology, vol. 23, no. 11, 2022, p. e480. https://doi.org/10.1016/s1470-2045(22)00628-3.
Chicago
Fiteni, Frédéric. 2022. “Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials.” The Lancet Oncology 23 (11): e480. https://doi.org/10.1016/s1470-2045(22)00628-3.
Harvard
Fiteni, F. (2022) ‘Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials’, The Lancet Oncology, 23(11), p. e480. doi:10.1016/s1470-2045(22)00628-3.
IEEE
F. Fiteni, “Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials,” The Lancet Oncology, vol. 23, no. 11, p. e480, 2022, doi: 10.1016/s1470-2045(22)00628-3.
BibTeX
@article{fiteni2022appropriateness,
title = {{Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials}},
author = {Fiteni, Frédéric},
journal = {The Lancet Oncology},
year = {2022},
volume = {23},
number = {11},
pages = {e480},
doi = {10.1016/s1470-2045(22)00628-3},
url = {https://doi.org/10.1016/s1470-2045(22)00628-3}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- ovarian cancer
- clinical trial endpoints
- survival
- quality of life
- toxicity
- composite endpoints
- consensus recommendations
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Fiteni, F. (2022). Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials. The Lancet Oncology, 23(11), e480. https://doi.org/10.1016/s1470-2045(22)00628-3
How many times has this paper been cited?
0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Frédéric Fiteni.
What is the DOI of this paper?
10.1016/s1470-2045(22)00628-3, permanently at https://doi.org/10.1016/s1470-2045(22)00628-3. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.